Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

2020 Nature 1,546 citations

Keywords

ReactogenicityImmunogenicityMedicineTolerabilityVirologyVaccinationPandemicCoronavirusAdverse effectImmunologyCoronavirus disease 2019 (COVID-19)Internal medicinePharmacologyAntibodyDiseaseInfectious disease (medical specialty)

MeSH Terms

AdultAntibodiesNeutralizingAntibodiesViralCOVID-19COVID-19 VaccinesCoronavirus InfectionsFemaleHumansImmunizationPassiveImmunoglobulin GMaleMiddle AgedPandemicsPneumoniaViralSpike GlycoproteinCoronavirusTime FactorsViral VaccinesYoung AdultCOVID-19 Serotherapy

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
586
Issue
7830
Pages
589-593
Citations
1546
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1546
OpenAlex
0
Influential

Cite This

Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin et al. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature , 586 (7830) , 589-593. https://doi.org/10.1038/s41586-020-2639-4

Identifiers

DOI
10.1038/s41586-020-2639-4
PMID
32785213

Data Quality

Data completeness: 72%